Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.08
EW's Cash-to-Debt is ranked lower than
61% of the 335 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. EW: 1.08 )
Ranked among companies with meaningful Cash-to-Debt only.
EW' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 1.11 Max: N/A
Current: 1.08
Equity-to-Asset 0.57
EW's Equity-to-Asset is ranked lower than
61% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. EW: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
EW' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.6 Max: 0.74
Current: 0.57
0.37
0.74
Interest Coverage 105.14
EW's Interest Coverage is ranked higher than
52% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: 73.23 vs. EW: 105.14 )
Ranked among companies with meaningful Interest Coverage only.
EW' s Interest Coverage Range Over the Past 10 Years
Min: 18.97  Med: 63.1 Max: 118.46
Current: 105.14
18.97
118.46
Piotroski F-Score: 6
Altman Z-Score: 10.06
Beneish M-Score: -2.20
WACC vs ROIC
7.04%
31.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 28.04
EW's Operating Margin % is ranked higher than
95% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. EW: 28.04 )
Ranked among companies with meaningful Operating Margin % only.
EW' s Operating Margin % Range Over the Past 10 Years
Min: 13.99  Med: 22.1 Max: 53.09
Current: 28.04
13.99
53.09
Net Margin % 20.85
EW's Net Margin % is ranked higher than
91% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. EW: 20.85 )
Ranked among companies with meaningful Net Margin % only.
EW' s Net Margin % Range Over the Past 10 Years
Min: 10.36  Med: 16.35 Max: 34.92
Current: 20.85
10.36
34.92
ROE % 25.60
EW's ROE % is ranked higher than
93% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. EW: 25.60 )
Ranked among companies with meaningful ROE % only.
EW' s ROE % Range Over the Past 10 Years
Min: 14.26  Med: 20.89 Max: 43.42
Current: 25.6
14.26
43.42
ROA % 15.25
EW's ROA % is ranked higher than
93% of the 336 Companies
in the Global Medical Devices industry.

( Industry Median: 0.33 vs. EW: 15.25 )
Ranked among companies with meaningful ROA % only.
EW' s ROA % Range Over the Past 10 Years
Min: 8.72  Med: 13.18 Max: 26.03
Current: 15.25
8.72
26.03
ROC (Joel Greenblatt) % 85.94
EW's ROC (Joel Greenblatt) % is ranked higher than
92% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.51 vs. EW: 85.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EW' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 41.35  Med: 57.83 Max: 138.73
Current: 85.94
41.35
138.73
3-Year Revenue Growth Rate 14.80
EW's 3-Year Revenue Growth Rate is ranked higher than
77% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. EW: 14.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EW' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 11.5 Max: 15.1
Current: 14.8
-9.7
15.1
3-Year EBITDA Growth Rate 14.00
EW's 3-Year EBITDA Growth Rate is ranked higher than
57% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. EW: 14.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EW' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.2  Med: 16 Max: 57.8
Current: 14
-20.2
57.8
3-Year EPS without NRI Growth Rate 15.10
EW's 3-Year EPS without NRI Growth Rate is ranked higher than
65% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. EW: 15.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EW' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 20.85 Max: 288.2
Current: 15.1
0
288.2
GuruFocus has detected 3 Warning Signs with Edwards Lifesciences Corp $EW.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EW's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NYSE:ZBH, NYSE:STJ, OTCPK:SNNUF, NAS:ISRG, NAS:ALGN, NYSE:BSX, OTCPK:SONVY, NYSE:VAR, NYSE:TFX, OTCPK:CNVVY, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:WILLF, NAS:ABMD, NAS:MASI, OTCPK:FSPKF, OTCPK:GGNDF, NAS:IART, NAS:NUVA, OTCPK:EKTAF » details
Traded in other countries:EWL.Germany, EW.Switzerland,
Headquarter Location:USA
Edwards Lifesciences Corp technologies treat structural heart disease and critically ill patients. It manufactures heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of heart disease. Its key products include tissue heart valves, surgical clips, catheters and retractors, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.

Guru Investment Theses on Edwards Lifesciences Corp

David Rolfe Comments on Edwards Lifesciences - Apr 14, 2017

We established a new position in Edwards Lifesciences (NYSE:EW) in the first quarter. Edwards is a pioneer in heart valve surgery, with nearly 90% of its revenues tied to heart valve replacement, by virtue of its best-in-class portfolio of intellectual property, backed by a relatively lengthy history of clinical data and successful outcomes. Heart disease is the world’s leading killer, and the incidence of heart disease grows with age, meaning that the aging of populations across the developed world is directly leading to a rise in the occurrence of heart problems. Over half of the Company’s business is tied to the rapidly-growing TAVR, or Transcatheter Aortic Valve Replacement, category. TAVR—as opposed to SAVR, which is Surgical Aortic Valve Replacement, which is generally a type of open-heart surgery—is a fairly recent technological advancement, with the first human procedure occurring in 2002; the first market approval in Europe in 2007; and US approval in 2011. We view TAVR, which replaces a heart valve using a small incision, usually in a patient’s leg, as clearly superior to traditional open-heart surgery, with similar clinical results at a comparable price, but without the need to crack open a patient’s chest. As the market for TAVR has developed, it was first approved for patients for whom traditional surgery was too risky to be a viable option, followed by patients for whom surgery was considered a high risk. 2016 saw a surge in procedures as TAVR was approved for patients for whom surgery is an intermediate risk, and clinical trials are underway to seek approval for low-risk patients, as well.

EW is the clear market leader in the TAVR segment of the market, and we expect its TAVR solutions to continue to gain significant share industry-wide over time as the procedure spreads into the low-risk patient population, especially as regulatory issues constraining the growth of the procedure ease over time, and as the industry invests in patient and physician education to expand the overall valve-replacement population, well beyond prior expectations. In addition, there are a significant amount of underserved populations among patients not yet showing symptoms and patients who might not have considered treatment previously, when the only option was to have their chests cracked open. We believe, over time, that TAVR’s superior, much less invasive treatment option could lead to earlier screening of asymptomatic patients, as well as to patients proactively inquiring about therapy.

On the valuation front, the stock looks attractive in relation to peers and the broader market, having pulled back almost a third from its highs, down to the middle of its historical valuation range, after the past few quarters of earnings results slightly underperformed versus very high expectations. Specifically, there was a temporary issue with France running out of money in its budget for TAVR reimbursement, as the budget had not anticipated the tremendous growth in TAVR procedures for intermediate-risk patients. We view this as a non-issue, longer-term. Further, the sequential growth rate for TAVR revenues slowed in the second half of 2016, despite a continuation of extremely healthy year-over-year growth, which registered nearly 30% globally and nearly 40% in the US in the fourth quarter, for example. We view this as very attractive growth and understand that there will be fits and starts in sequential growth rates around product approval cycles. Longer-term, we view Edwards as an attractive growth opportunity, as aging populations lead to increasing heart disease, and as TAVR takes share within the valve-replacement market. We see opportunities for growth within the established patient population, in addition to current estimates of the patient population that we think are significantly understated, meaning that the market’s long-term growth expectations are also understated. We believe the under-appreciated growth opportunities, the secular shift towards less invasive procedures, and the reasonable valuation makes EW an attractive long-term holding.

From David Rolfe (Trades, Portfolio)'s Wedgewood Partners first-quarter 2017 shareholder letter.

Check out David Rolfe latest stock trades

Baron Opportunity Fund Comments on Edwards - Feb 21, 2017

Edwards (NYSE:EW) is the world’s leading manufacturer of tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve. Edwards has leveraged the knowledge and experience from its surgical tissue heart valve business to develop transcatheter heart valve replacement technologies, designed to treat heart valve disease using catheter-based approaches as opposed to open surgery. Transcatheter aortic valve replacement (TAVR) is an innovative procedure in which a valve is inserted through a catheter and implanted within the diseased aortic valve. The procedure is significantly less invasive than surgery, takes about 90 minutes and recovery can be as short as a few days. TAVR is transforming the market because it provides a new, less invasive treatment option for patients ineligible for surgery or at high surgical risk. Edwards believes there are about 650,000 aortic stenosis patients addressable with TAVR–over twice their prior view of the addressable market–only a fraction of which are being treated with TAVR today. Edwards is also investing in transcatheter valve technologies to treat patients with mitral and tricuspid diseases–which present large, untapped addressable markets (2.5 million for mitral and 1.5 million for tricuspid)–and have the potential to open up significant new growth opportunities for the company.



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Edwards Lifesciences Corp

Edwards Lifesciences To Present At Goldman Sachs 38th Annual Global Healthcare Conference
Edwards SAPIEN 3 Valve Receives FDA Approval For Aortic, Mitral Valve-In-Valve Procedures
David Rolfe's Quest for 'Huge Winners' The guru behind the RiverPark/Wedgewood Fund counts on occasional big gains to maintain benchmark-beating returns
David Rolfe (Trades, Portfolio) of Wedgewood Partners Inc. is one of the GuruFocus gurus who’s beaten the Standard & Poor's 500 on most cumulative returns over the past two decades. Read more...
Paul Tudor Jones’ Top 4 Health Care Buys Guru invested in multiple health care stocks in 1st quarter
Paul Tudor Jones (Trades, Portfolio)’ Tudor Investment Corp. gained 325 new holdings during the first quarter. Among his purchases were multiple health care stocks including VCA Inc. (NASDAQ:WOOF), DaVita Inc. (NYSE:DVA), Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) and Edwards Lifesciences Corp. (NYSE:EW). Read more...
David Rolfe Gains 3 Holdings, Sells 2 Others in 1st Quarter Guru reports quarterly portfolio
Wedgewood Partners’ David Rolfe (Trades, Portfolio) gained three new holdings during the first quarter and sold two others. His new positions are Edwards Lifesciences Corp. (NYSE:EW), Celgene Corp. (NASDAQ:CELG) and Boeing Co. (NYSE:BA). Read more...
Real-World Evidence With Edwards SAPIEN 3 Transcatheter Valve Confirms Beneficial Patient Outcomes From Clinical Trials
Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
Edwards Lifesciences To Present At The Deutsche Bank 42nd Annual Health Care Conference
Edwards' Advanced Hemodynamic Monitoring Platform Receives FDA Clearance
David Rolfe Comments on Edwards Lifesciences Guru stock highlight
We established a new position in Edwards Lifesciences (NYSE:EW) in the first quarter. Edwards is a pioneer in heart valve surgery, with nearly 90% of its revenues tied to heart valve replacement, by virtue of its best-in-class portfolio of intellectual property, backed by a relatively lengthy history of clinical data and successful outcomes. Heart disease is the world’s leading killer, and the incidence of heart disease grows with age, meaning that the aging of populations across the developed world is directly leading to a rise in the occurrence of heart problems. Over half of the Company’s business is tied to the rapidly-growing TAVR, or Transcatheter Aortic Valve Replacement, category. TAVR—as opposed to SAVR, which is Surgical Aortic Valve Replacement, which is generally a type of open-heart surgery—is a fairly recent technological advancement, with the first human procedure occurring in 2002; the first market approval in Europe in 2007; and US approval in 2011. We view TAVR, which replaces a heart valve using a small incision, usually in a patient’s leg, as clearly superior to traditional open-heart surgery, with similar Read more...

Ratios

vs
industry
vs
history
PE Ratio 39.33
EW's PE Ratio is ranked lower than
61% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 31.71 vs. EW: 39.33 )
Ranked among companies with meaningful PE Ratio only.
EW' s PE Ratio Range Over the Past 10 Years
Min: 11.18  Med: 28.8 Max: 50.58
Current: 39.33
11.18
50.58
Forward PE Ratio 34.36
EW's Forward PE Ratio is ranked lower than
65% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. EW: 34.36 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 39.33
EW's PE Ratio without NRI is ranked lower than
61% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 31.15 vs. EW: 39.33 )
Ranked among companies with meaningful PE Ratio without NRI only.
EW' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.16  Med: 28.64 Max: 49.62
Current: 39.33
11.16
49.62
Price-to-Owner-Earnings 47.15
EW's Price-to-Owner-Earnings is ranked lower than
65% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 37.27 vs. EW: 47.15 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
EW' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.88  Med: 36.44 Max: 572.5
Current: 47.15
7.88
572.5
PB Ratio 9.12
EW's PB Ratio is ranked lower than
88% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. EW: 9.12 )
Ranked among companies with meaningful PB Ratio only.
EW' s PB Ratio Range Over the Past 10 Years
Min: 2.9  Med: 5.75 Max: 10.16
Current: 9.12
2.9
10.16
PS Ratio 8.18
EW's PS Ratio is ranked lower than
79% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.36 vs. EW: 8.18 )
Ranked among companies with meaningful PS Ratio only.
EW' s PS Ratio Range Over the Past 10 Years
Min: 2.31  Med: 4.89 Max: 9.42
Current: 8.18
2.31
9.42
Price-to-Free-Cash-Flow 49.77
EW's Price-to-Free-Cash-Flow is ranked lower than
70% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 32.05 vs. EW: 49.77 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EW' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.82  Med: 39.05 Max: 517.1
Current: 49.77
7.82
517.1
Price-to-Operating-Cash-Flow 35.49
EW's Price-to-Operating-Cash-Flow is ranked lower than
77% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 20.50 vs. EW: 35.49 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EW' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.33  Med: 27.74 Max: 48.87
Current: 35.49
7.33
48.87
EV-to-EBIT 28.98
EW's EV-to-EBIT is ranked lower than
56% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 24.85 vs. EW: 28.98 )
Ranked among companies with meaningful EV-to-EBIT only.
EW' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 21.05 Max: 39.7
Current: 28.98
6.8
39.7
EV-to-EBITDA 26.60
EW's EV-to-EBITDA is ranked lower than
68% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 18.30 vs. EW: 26.60 )
Ranked among companies with meaningful EV-to-EBITDA only.
EW' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 16.7 Max: 33.5
Current: 26.6
6.4
33.5
PEG Ratio 1.70
EW's PEG Ratio is ranked higher than
68% of the 84 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. EW: 1.70 )
Ranked among companies with meaningful PEG Ratio only.
EW' s PEG Ratio Range Over the Past 10 Years
Min: 0.45  Med: 1.37 Max: 3.48
Current: 1.7
0.45
3.48
Shiller PE Ratio 68.62
EW's Shiller PE Ratio is ranked lower than
71% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 47.49 vs. EW: 68.62 )
Ranked among companies with meaningful Shiller PE Ratio only.
EW' s Shiller PE Ratio Range Over the Past 10 Years
Min: 34.67  Med: 62.23 Max: 124.24
Current: 68.62
34.67
124.24
Current Ratio 3.45
EW's Current Ratio is ranked higher than
63% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. EW: 3.45 )
Ranked among companies with meaningful Current Ratio only.
EW' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.68 Max: 5.56
Current: 3.45
0.89
5.56
Quick Ratio 2.71
EW's Quick Ratio is ranked higher than
64% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. EW: 2.71 )
Ranked among companies with meaningful Quick Ratio only.
EW' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.09 Max: 4.83
Current: 2.71
0.49
4.83
Days Inventory 171.23
EW's Days Inventory is ranked lower than
64% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 131.96 vs. EW: 171.23 )
Ranked among companies with meaningful Days Inventory only.
EW' s Days Inventory Range Over the Past 10 Years
Min: 132.4  Med: 170.89 Max: 208.39
Current: 171.23
132.4
208.39
Days Sales Outstanding 59.12
EW's Days Sales Outstanding is ranked higher than
62% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. EW: 59.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
EW' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.74  Med: 54.46 Max: 69.95
Current: 59.12
38.74
69.95
Days Payable 40.76
EW's Days Payable is ranked lower than
67% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 55.39 vs. EW: 40.76 )
Ranked among companies with meaningful Days Payable only.
EW' s Days Payable Range Over the Past 10 Years
Min: 33.96  Med: 45.59 Max: 63.34
Current: 40.76
33.96
63.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.10
EW's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. EW: 1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EW' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.2  Med: 0.5 Max: 2.2
Current: 1.1
-1.2
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 17.91
EW's Price-to-Tangible-Book is ranked lower than
90% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 3.91 vs. EW: 17.91 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EW' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.58  Med: 10.02 Max: 199.7
Current: 17.91
5.58
199.7
Price-to-Intrinsic-Value-Projected-FCF 2.81
EW's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
60% of the 143 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. EW: 2.81 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EW' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.35  Med: 2 Max: 3.62
Current: 2.81
1.35
3.62
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.38
EW's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
79% of the 28 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. EW: 1.38 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.67
EW's Price-to-Median-PS-Value is ranked lower than
82% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. EW: 1.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EW' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 0.63 Max: 1.88
Current: 1.67
0.26
1.88
Price-to-Peter-Lynch-Fair-Value 1.87
EW's Price-to-Peter-Lynch-Fair-Value is ranked higher than
58% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. EW: 1.87 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
EW' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.46 Max: 3.27
Current: 1.87
0.59
3.27
Price-to-Graham-Number 5.60
EW's Price-to-Graham-Number is ranked lower than
83% of the 142 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. EW: 5.60 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EW' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.81  Med: 3.54 Max: 29.59
Current: 5.6
1.81
29.59
Earnings Yield (Greenblatt) % 3.45
EW's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. EW: 3.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EW' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.5  Med: 4.75 Max: 14.7
Current: 3.45
2.5
14.7
Forward Rate of Return (Yacktman) % 22.91
EW's Forward Rate of Return (Yacktman) % is ranked higher than
84% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 8.76 vs. EW: 22.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
EW' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 15.1  Med: 23 Max: 37.5
Current: 22.91
15.1
37.5

More Statistics

Revenue (TTM) (Mil) $3,149.90
EPS (TTM) $ 3.01
Beta0.84
Short Percentage of Float1.09%
52-Week Range $81.12 - 121.75
Shares Outstanding (Mil)209.80

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,332 3,686 4,026
EPS ($) 3.44 4.03 4.57
EPS without NRI ($) 3.44 4.03 4.57
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.35%
Dividends per Share ($)
» More Articles for EW

Headlines

Articles On GuruFocus.com
GAMCO Analyst: Is VMware a Compelling Investment Idea in Data Infrastructure? Jun 26 2017 
Gabelli TV: 2017 American Water Works Annual Conference Recap Jun 26 2017 
Monthly Dividend Stocks to Pay Your Bills Jun 26 2017 
The Rubicon Project: Who Is Selling and Why It's Creating a Bargain Price Jun 26 2017 
Sports, Stocks and the Magic Quadrants Jun 26 2017 
GMO Global Equity Insights - Whiplash: On Value, Growth and Ignoring the Fundamentals Jun 26 2017 
Dan Loeb's Third Point Letter on $3.5 Billion Nestle Purchase, Plans to Sells L'Oreal Jun 26 2017 
Canaries in the Coal Mine – What to Watch as Stocks Continue to Make New Highs Jun 26 2017 
A Look at Darden Valuation Jun 26 2017 
Is Dollar Tree Oversold With Potential Cuts to SNAP? Jun 26 2017 

More From Other Websites
Edwards Lifesciences Wins a Patent Case against Neovasc Jun 26 2017
FDA Approves Edwards Lifesciences’ Sapien 3 Valve for Expanded Indication Jun 26 2017
Edwards Lifesciences Gets ‘Buy’ Ratings from 77% of Analysts Jun 26 2017
Why Investors Should Buy Edwards Lifesciences (EW) Right Now Jun 22 2017
Heart Valve Maker Trying To Pump Stock Past Buy Zone Jun 20 2017
A Focus On These Leading Stocks Is Helping This MFS Mutual Fund Outperform The Market Jun 08 2017
Edwards Lifesciences To Present At Goldman Sachs 38th Annual Global Healthcare Conference Jun 06 2017
Edwards Lifesciences (EW) SAPIEN 3 THV Gets FDA Approval Jun 06 2017
FDA approves new use for Edwards' Sapien 3 heart valve Jun 05 2017
Edwards SAPIEN 3 Valve Receives FDA Approval For Aortic, Mitral Valve-In-Valve Procedures Jun 05 2017
Inogen Secures New Direct-to-Consumer Business Facility Jun 05 2017
RTI Surgical Now Part of US-Based Manufacturing Initiative Jun 05 2017
Quintiles IMS Holdings (Q) Holds Secondary Offering (revised) Jun 02 2017
The Cooper Companies (COO) Beats Earnings Estimates in Q2 Jun 02 2017
Edwards Lifesciences' TAVR & International Prospects Solid Jun 02 2017
What Results Did Edwards Lifesciences’ Centera Valve Study Yield? Jun 01 2017
Discussing Edwards Lifesciences’ Recent Stock Movements May 31 2017
LabCorp Trades Down on Weak 2017 View, Reimbursement Woes May 31 2017
Analysts’ Latest Recommendations for Edwards Lifesciences May 31 2017
Top Stock Picks for the Week of May 29th May 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}